Genetic determinants of circulating interleukin-1 receptor antagonist levels and their association with glycemic traits
- PMID: 24969107
- PMCID: PMC4237993
- DOI: 10.2337/db14-0731
Genetic determinants of circulating interleukin-1 receptor antagonist levels and their association with glycemic traits
Abstract
The proinflammatory cytokine interleukin (IL)-1β is implicated in the development of insulin resistance and β-cell dysfunction, whereas higher circulating levels of IL-1 receptor antagonist (IL-1RA), an endogenous inhibitor of IL-1β, has been suggested to improve glycemia and β-cell function in patients with type 2 diabetes. To elucidate the protective role of IL-1RA, this study aimed to identify genetic determinants of circulating IL-1RA concentration and to investigate their associations with immunological and metabolic variables related to cardiometabolic risk. In the analysis of seven discovery and four replication cohort studies, two single nucleotide polymorphisms (SNPs) were independently associated with circulating IL-1RA concentration (rs4251961 at the IL1RN locus [n = 13,955, P = 2.76 × 10(-21)] and rs6759676, closest gene locus IL1F10 [n = 13,994, P = 1.73 × 10(-17)]). The proportion of the variance in IL-1RA explained by both SNPs combined was 2.0%. IL-1RA-raising alleles of both SNPs were associated with lower circulating C-reactive protein concentration. The IL-1RA-raising allele of rs6759676 was also associated with lower fasting insulin levels and lower HOMA insulin resistance. In conclusion, we show that circulating IL-1RA levels are predicted by two independent SNPs at the IL1RN and IL1F10 loci and that genetically raised IL-1RA may be protective against the development of insulin resistance.
© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
Figures
Similar articles
-
Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis.Lancet Diabetes Endocrinol. 2015 Apr;3(4):243-53. doi: 10.1016/S2213-8587(15)00034-0. Epub 2015 Feb 26. Lancet Diabetes Endocrinol. 2015. PMID: 25726324 Free PMC article.
-
Genome-wide associated loci influencing interleukin (IL)-10, IL-1Ra, and IL-6 levels in African Americans.Immunogenetics. 2012 May;64(5):351-9. doi: 10.1007/s00251-011-0596-7. Epub 2011 Dec 29. Immunogenetics. 2012. PMID: 22205395 Free PMC article.
-
Genetic variation of the interleukin-1 family and nongenetic factors determining the interleukin-1 receptor antagonist phenotypes.Metabolism. 2010 Oct;59(10):1520-7. doi: 10.1016/j.metabol.2010.01.017. Epub 2010 Feb 23. Metabolism. 2010. PMID: 20178882
-
IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?FEBS Lett. 2006 Nov 27;580(27):6289-94. doi: 10.1016/j.febslet.2006.10.061. Epub 2006 Nov 3. FEBS Lett. 2006. PMID: 17097645 Review.
-
Interleukin-1 receptor antagonist, interleukin-2 receptor alpha subunit and amyotrophic lateral sclerosis.Eur J Neurol. 2020 Oct;27(10):1913-1917. doi: 10.1111/ene.14338. Epub 2020 Jun 8. Eur J Neurol. 2020. PMID: 32441415 Review.
Cited by
-
Inflammation and Brain Structure in Alzheimer's Disease and Other Neurodegenerative Disorders: a Mendelian Randomization Study.Mol Neurobiol. 2024 Mar;61(3):1593-1604. doi: 10.1007/s12035-023-03648-6. Epub 2023 Sep 22. Mol Neurobiol. 2024. PMID: 37736795
-
Interleukin-38 promoter variants and risk of COVID-19 among Iraqis.Immunobiology. 2022 Nov;227(6):152301. doi: 10.1016/j.imbio.2022.152301. Epub 2022 Nov 9. Immunobiology. 2022. PMID: 36375233 Free PMC article.
-
Interleukin-1 in Coronary Artery Disease.Curr Top Med Chem. 2022;22(28):2368-2389. doi: 10.2174/1568026623666221017144734. Curr Top Med Chem. 2022. PMID: 36263481
-
IL-1 Receptor Antagonist (IL-1Ra) Levels and Management of Metabolic Disorders.Nutrients. 2022 Aug 19;14(16):3422. doi: 10.3390/nu14163422. Nutrients. 2022. PMID: 36014927 Free PMC article.
-
A Mendelian randomization study investigating the causal role of inflammation on Parkinson's disease.Brain. 2022 Oct 21;145(10):3444-3453. doi: 10.1093/brain/awac193. Brain. 2022. PMID: 35656776 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
- R01 HL036310/HL/NHLBI NIH HHS/United States
- RG/07/008/23674/BHF_/British Heart Foundation/United Kingdom
- MC_UU_12015/1/MRC_/Medical Research Council/United Kingdom
- MR/K006584/1/MRC_/Medical Research Council/United Kingdom
- RG/13/2/30098/BHF_/British Heart Foundation/United Kingdom
- RG/10/12/28456/BHF_/British Heart Foundation/United Kingdom
- R01 AG013196/AG/NIA NIH HHS/United States
- 5R01-AG-13196/AG/NIA NIH HHS/United States
- HS06516/HS/AHRQ HHS/United States
- G0501184/MRC_/Medical Research Council/United Kingdom
- MC_U106179471/MRC_/Medical Research Council/United Kingdom
- R01-HL-036310/HL/NHLBI NIH HHS/United States
- MR/K013351/1/MRC_/Medical Research Council/United Kingdom
- K013351/MRC_/Medical Research Council/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
